Vergleich

Recombinant Human TNFRSF17/BCMA Protein (Fc Tag)

ArtNr ELS-PKSH031502-200ug
Hersteller Elabscience
Menge 200 ug
Quantity options 200 ug 50 ug 100 ug 1 mg
Kategorie
Typ Proteins
Format Lyophilized Powder
Specific against Human (Homo sapiens)
Host HEK293 cells
Konjugat/Tag N-rFc
Purity > 95 % as determined by reducing SDS-PAGE.
Sequence Met 1-Ala54
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias BCM, BCMA, CD269, TNFRSF13A
Similar products CD269, BCMA, BCM, TNFRSF13A
Versandbedingung Gekühlt
Lieferbar
Manufacturer - Category
Recombinant Proteins / Others
Manufacturer - Conjugate / Tag
N-rFc
Shipping Temperature
This product is provided as lyophilized powder which is shipped with ice packs.
Storage Conditions
Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Calculated Molecular Weight
33.3 kDa
Manufacturer - Research Areas
Signal Transduction, Cancer, immunology,
Background
Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method.
Reconstitution
Please refer to the printed manual for detailed information.
Formulation
Lyophilized from sterile PBS, pH 7.4
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Activity
Not validated for activity

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 200 ug
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?